-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: Technical Advantages of PDC High-Throughput In Vitro Drug Efficacy Platform
Author:
InnoModels
Release time:
2024-04-03
In the field of drug discovery and development, how to accurately and efficiently assess the effects and safety of drugs has always been the goal of scientists. InnoModels' PDC high-throughput in vitro drug efficacy platform brings a new breakthrough in this field with its unique technology and advantages.
1. Highly Consistent Primary Cells
Using the digestion products of PDX (patient-derived xenograft) models, the PDC high-throughput in vitro pharmacodynamic platform of InnoModels Biotechnology has successfully obtained primary cells that are highly consistent with patients. These primary cells not only have complex cell subpopulations, but also retain authentic biological characteristics, allowing the drug to act and respond more closely to the clinical situation. Compared with traditional cell lines, such highly consistent primary cells provide more accurate and reliable experimental data for drug development.
2、Efficient drug screening capability
The platform has a powerful high-throughput drug screening capability, which allows for rapid and accurate evaluation of a large number of drugs. By comparing the subject drug with counterpart drugs (e.g., drugs with similar mechanism of action or standardized therapeutic drugs), researchers can quickly screen out potential drug candidates and provide strong support for subsequent clinical trials.

3、Predicting the clinical effectiveness of drugs
In addition to drug screening, the platform can also predict the clinical effectiveness of drugs. By comparing the performance of the subject drug in in vitro experiments with the efficacy data of known drugs, researchers can initially determine the success rate of the drug in clinical trials. This prediction capability greatly shortens the drug development cycle, reduces R&D costs, and brings higher economic benefits to pharmaceutical companies.
4、Wide range of applications
InnoModels' PDC high-throughput in vitro drug efficacy platform is applicable to a wide range of drug development types, including antitumor drugs, antiviral drugs, and neurological drugs. In addition, the platform can also be used to evaluate drug resistance and safety, providing comprehensive technical support for drug development.
5. Conclusion
To summarize, the PDC high-throughput in vitro drug efficacy platform of InnoModels Biotechnology has brought significant technological innovation to the field of drug discovery and development with its high consistency of primary cells, highly efficient drug screening capability, predictive drug clinical efficacy, and wide range of applications. With the continuous optimization and improvement of the platform, it is believed that it will bring more innovations to pharmaceutical companies and research institutes, and promote the continuous development of the drug R&D field.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd